Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and Below

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age1-10
SponsorInternational Peace Maternity and Child Health Hospital

About this trial

It is intended to examine the short-term and long-term efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms born at 28 weeks and below. Participants will received continuous infusion IVIG 1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable if necessary.

Eligibility criteria

Qualifiers

Gestational age ≤ 28 weeks + 6 days

Admission within 24 hours after birth.

Infants show a suspicion of BPD, the diagnosis is suspected based on the following clinical manifestations and chest X-ray findings.

Disqualifiers

Major congenital anomalies(e.g., congenital heart disease, congenital craniocerebral deformity, congenital structural abnormality of respiratory system, congenital hereditary metabolic disease)

Chromosomal defects (e.g., trisomy 13, 18, 21)

Severe intracranial hemorrhage

Multiple organ failure

Trial design

Treatments tested in this trial

  • intravenous immunoglobulin

Treatment groups

29 Participants
are divided into 1 treatment group